Advertisement

Methylprednisolone Sodium Succinate Injection

[26 September 2016]

Products Affected - Description

All presentations are currently available

Reason for the Shortage

  • Fresenius Kabi states the reason for the shortage was increased demand.
  • Pfizer states the reason for the shortage was manufacturing delay.

Available Products

Solu-Medrol injection, Pfizer
1 gram, Act-O-Vial single dose vial, 1 count (NDC 00009-0018-20)
1 gram, single dose vial, 1 count (NDC 00009-0698-01)
2 gram, single dose vial, 1 count (NDC 00009-0796-01)
40 mg, Act-O-Vial single dose vial, 25 count (NDC 00009-0039-28)
125 mg, Act-O-Vial single dose vial, 25 count (NDC 00009-0047-22)
500 mg, single dose vial, 1 count (NDC 00009-0758-01)
500 mg, Act-O-Vial single dose vial, 1 count (NDC 00009-0003-02)
 
Methylprednisolone Sodium Succinate powder for solution for injection, Fresenius Kabi
1 gram, single dose vial, 1 count (NDC 63323-0265-30)
40 mg, single dose vial, 25 count (NDC 63323-0255-03)
125 mg, single dose vial, 25 count (NDC 63323-0258-03)

Estimated Resupply Dates

All presentations are currently available.

Related Shortages

Updated

September 26, August 1, July 15, June 14 and 9, May 27 and 2, April 28, March 2, February 22, January 28, 2016, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement
ASHP Product Listing